Mass. Movers

Aveo expects to raise $50m in offering

Aveo employees at work in the company’s lab.

Suzanne Kreiter/Globe staff/File

Aveo employees at work in the company’s lab.


Cambridge’s Aveo Pharmaceuticals Inc. rose on its offering of 6.7 million shares for $7.50 each. The company said it expects to raise about $50 million before discounts and commissions. The offering is expected to close on Wednesday. Aveo helped develop an experimental cancer pill — Tivopath — that is currently under review by the Food and Drug Administration to treat advanced kidney cancer. The agency is expected to finish its review by July.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of